Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn’s disease
Irmgard Kübler(Robert Bosch Hospital), Jan Wehkamp(Robert Bosch Hospital), Katja Rothfuss(Robert Bosch Hospital), Michael Gersemann(Robert Bosch Hospital), Maureen J. Koslowski(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Klaus Fellermann(Apple (Israel)), Julia Beisner(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Eduard F. Stange(John Radcliffe Hospital), Klaus Herrlinger(Robert Bosch Hospital), Sven Becker(Laboratoire National Henri Becquerel)
Cited by 21
Related Papers
Reduced Paneth cell α-defensins in ileal Crohn's disease
|Proceedings of the National Academy of Sciences|2005|969
NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression
|Gut|2004|798
A Chromosome 8 Gene-Cluster Polymorphism with Low Human Beta-Defensin 2 Gene Copy Number Predisposes to Crohn Disease of the Colon
|The American Journal of Human Genetics|2006|566
European evidence-based Consensus on the management of ulcerative colitis: Current management
|Journal of Crohn s and Colitis|2008|558